Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya.

Show simple item record

dc.contributor.author Estambale, Benson B.
dc.contributor.author Chunge, CN.
dc.contributor.author Pamba, HO.
dc.contributor.author Chitayi, PM.
dc.contributor.author Munanga, PN.
dc.contributor.author Kang'ethe, S.
dc.date.accessioned 2018-06-12T08:29:59Z
dc.date.available 2018-06-12T08:29:59Z
dc.date.issued 1989
dc.identifier.uri http://ir.jooust.ac.ke:8080/xmlui/handle/123456789/1268
dc.description.abstract Four antiamoebic drugs currently used in many Kenyan hospitals and health centres were compared for their efficacy on symptomatic luminal amoebiasis in Kiambu, Kilifi, and Machakos hospitals during this study. The drugs were; the brand metronidazole (Flagyl, May & Baker, Kenya Ltd.), the generic metronidazole (Metrozol, Cosmos Ltd., Nairobi, Kenya), the brand tinidazole (Fasigyn, Pfizer Laboratories Ltd.) and the generic tinidazole (Tynazole Laboratory and Allied Equipments, Kenya Ltd). Clinical cure was achieved in all individuals receiving any of the four drugs. Parasitological cure was better for those receiving either Flagyl or Fasigyn, than those receiving the generic counterparts. Both parasitological and clinical cures were achieved in about 50% of all those who received either Flagyl or Fasigyn. It appears that Flagyl and Fasigyn are not as efficacious as previously reported but are still much better than their generic counterparts for the treatment of symptomatic Entamoeba histolytica infections. en_US
dc.language.iso en en_US
dc.publisher PubMed en_US
dc.title Comparison of four nitroimidazole compounds for treatment of symptomatic amoebiasis in Kenya. en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account